Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Daiichi Sankyo Ltd ADR (OP: DSNKY ) 31.90 -0.38 (-1.18%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 48,192 Open 31.71 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 32.28 Today's Range 31.46 - 32.16 52wk Range 25.26 - 42.48 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients September 23, 2024 AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... Via Benzinga Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study September 17, 2024 Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... Via Benzinga Performance YTD +17.76% +17.76% 1 Month -2.98% -2.98% 3 Month -13.22% -13.22% 6 Month -7.16% -7.16% 1 Year +18.06% +18.06% More News Read More AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial September 10, 2024 Via Benzinga Is Merck Stock Undervalued After Its Colossal Earnings Growth? September 07, 2024 Via MarketBeat DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024 August 13, 2024 Via InvestorPlace Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact March 20, 2023 Via Benzinga Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 August 07, 2024 Via Benzinga Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast July 30, 2024 Via Benzinga Exposures Product Safety The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 July 15, 2024 Via InvestorPlace FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug June 27, 2024 Via Benzinga Exposures Product Safety Why Is AstraZeneca Stock Trading Lower On Tuesday? May 28, 2024 Via Benzinga DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 April 30, 2024 Via InvestorPlace Double Good News For AstraZeneca's Breast Cancer Drugs April 29, 2024 Via Benzinga AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor April 08, 2024 Via Benzinga Exposures Product Safety What's Going On With Pfizer Stock Today? January 25, 2024 Via Benzinga Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today January 03, 2024 Via Benzinga Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider December 20, 2023 Via Benzinga Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? October 31, 2023 Via The Motley Fool Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting September 22, 2023 Via Benzinga AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials September 11, 2023 Via Benzinga FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt July 21, 2023 Via Benzinga Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 Via Benzinga AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial July 03, 2023 Via Benzinga Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines June 27, 2023 Via Benzinga AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting March 06, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
